GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Larimar Therapeutics
The shares of Larimar, a biotech focused on treating rare diseases, reflect the potential of its lead drug. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Pharma neurology
Larimar Therapeutics is a clinical-stage biotechnology company developing therapies for rare diseases caused by protein deficiencies, specifically Friedreich's ataxia. We have classified it in the "Pharma Neurology" segment. The chart below shows the overall dynamics of the pharmaceutical sector focused on neurological and rare diseases.
Broad Market Index - GURU.Markets
Larimar Therapeutics is a biopharmaceutical company developing treatments for rare diseases associated with frataxin deficiency. As a component of the GURU.Markets index, it represents the orphan disease sector. The chart below represents the entire market. See how Larimar shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
LRMR - Daily change in the company's share price Larimar Therapeutics
For Larimar Therapeutics, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess neuroscience risk.
Daily change in the price of a set of shares in a market segment - Pharma neurology
Larimar Therapeutics, Inc. is a biotech company. This chart demonstrates the extreme volatility of the sector. Comparison with LRMR, which focuses on rare disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Larimar is a biopharmaceutical company developing drugs to treat rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Larimar's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Larimar Therapeutics
Larimar Therapeutics' year-to-date performance is a story of developing a therapy for a rare genetic disorder, Friedreich's ataxia. Its 12-month market cap is fundamentally dependent on FDA decisions and clinical trial data. The lifting of regulatory restrictions and progress in research are fundamental events shaping its future.
Annual dynamics of market capitalization of the market segment - Pharma neurology
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company developing drugs for the treatment of rare diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Larimar Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Larimar Therapeutics
The performance of Larimar, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of its clinical trials for a drug treating a rare neurological disease, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
Larimar Therapeutics is a clinical-stage biotech company developing a drug for the treatment of Friedreich's ataxia, a rare neurological disorder. Its valuation is entirely dependent on trial results. The neuroscience segment dynamics chart will reveal overall investor interest in this complex area, which provides a backdrop for assessing Larimar's risks.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Larimar Therapeutics develops drugs to treat rare diseases. Like many biotech companies in the research stage, its shares follow their own rhythm. Monthly performance is determined not by market trends, but by news about the progress of clinical trials. The chart clearly demonstrates this independence from overall investor sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Larimar Therapeutics
Larimar Therapeutics, a biotech company developing treatments for rare diseases, exhibits extreme volatility. Its weekly stock price is almost always a direct reaction to FDA decisions or the release of clinical trial data, which can cause the price to change dramatically in a short period of time.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
Neuroscience-focused biotech companies like Larimar often move together, driven by shared news of breakthroughs or setbacks in brain disease treatments. The chart below illustrates this general sentiment within the niche. It allows one to gauge the market's confidence in Larimar's drugs compared to competitors' developments.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Larimar Therapeutics is a biotech company whose fate hinges on the success of its single lead drug. It's a classic case of "make or break." The chart below shows how its shares navigate a world of their own, where a single trial announcement can trigger moves that defy the entire market.
Market capitalization of the company, segment and market as a whole
LRMR - Market capitalization of the company Larimar Therapeutics
Larimar Therapeutics' market capitalization represents the financial value of its hopes for a treatment for the rare genetic disorder Friedreich's ataxia. This chart shows how investors are reacting to news of clinical trials for its lead drug. Its high volatility and price reflect the potential of this first-of-its-kind treatment.
LRMR - Share of the company's market capitalization Larimar Therapeutics within the market segment - Pharma neurology
Larimar Therapeutics is a biopharmaceutical company developing treatments for rare diseases associated with protein deficiencies. Its share of the neuroscience segment's market capitalization is entirely dependent on the progress of its clinical trials. Its growth reflects investor hopes for the approval of its key drug and its market launch.
Market capitalization of the market segment - Pharma neurology
Here's a chart reflecting the combined weight of the entire neuroscience pharmaceutical sector. It's a trillion-dollar market in search of a breakthrough. For Larimar Therapeutics, which develops drugs for rare diseases, the rise in this chart reflects investors' faith in science. Every fluctuation is a reaction to the successes or failures of the entire industry in the complex fight against brain diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Larimar Therapeutics develops drugs to treat rare diseases caused by protein deficiencies. Its market capitalization represents the concentrated hope of a breakthrough in orphan medicine. This represents the share of the overall market that investors are investing in saving lives with rare diagnoses.
Book value capitalization of the company, segment and market as a whole
LRMR - Book value capitalization of the company Larimar Therapeutics
Larimar Therapeutics develops therapies for rare diseases. Its book value represents its financial resources for research. It consists of cash that allows the company to conduct clinical trials of its lead candidate. How has this vital capital evolved? The chart below shows this story.
LRMR - Share of the company's book capitalization Larimar Therapeutics within the market segment - Pharma neurology
Larimar Therapeutics develops therapies for rare diseases, and its scientific ambitions require a material base. This includes research laboratories and investments in manufacturing processes for the creation of complex protein drugs. The chart shows the company's share of the physical R&D infrastructure in this specific biopharma segment.
Market segment balance sheet capitalization - Pharma neurology
Larimar Therapeutics, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Larimar Therapeutics' balance sheet isn't its plants, but its scientific platform and intellectual property for drugs for rare protein deficiency diseases. The company's assets are capitalized research. The chart shows how these intangible, yet potentially valuable, assets are valued.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Larimar Therapeutics
Larimar's balance sheet is capitalized R&D costs. Its entire market value is a premium on the hope for success of its Friedreich's ataxia drug. The graph is a visualization of these hopes, which could either materialize or vanish after the trial data is published.
Market to book capitalization ratio in a market segment - Pharma neurology
Larimar Therapeutics is a biotech company developing therapies for rare diseases. Its valuation on this chart is heavily dependent on clinical trial news. This is a classic biotech story, where one successful outcome can lead to explosive market growth.
Market to book capitalization ratio for the market as a whole
Larimar Therapeutics is a biotech company developing drugs for rare diseases. Its market value depends almost entirely on the success of its lead candidate's clinical trials. This is a prime example of how investor expectations create a valuation unrelated to current book value.
Debts of the company, segment and market as a whole
LRMR - Company debts Larimar Therapeutics
Larimar Therapeutics, a clinical-stage biotech, uses capital to develop treatments for rare diseases. The funding, including potential debt, is used to conduct expensive trials. This chart shows how the company manages its resources amidst the high scientific uncertainty of developing a new drug.
Market segment debts - Pharma neurology
Larimar Therapeutics is a clinical-stage biotech company focused on rare diseases. Such companies rely almost entirely on equity for funding, as the lack of revenue makes debt extremely risky. This chart likely reflects minimal leverage, as is the industry norm.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Larimar Therapeutics
Larimar Therapeutics is a clinical-stage biotech company. Debt is a way for the company to finance research until drug approval. This chart shows the financial risk the company bears. An increase in this indicator indicates that the company is approaching important research milestones, but also increases its dependence on their successful outcome.
Market segment debt to market segment book capitalization - Pharma neurology
Larimar Therapeutics develops drugs to treat rare diseases associated with protein deficiencies. Biotechnology is a field with enormous risks and potential breakthroughs. The chart shows how aggressively the sector uses debt to fund multi-year clinical trials, providing context for assessing Larimar's strategy.
Debt to book value of all companies in the market
Larimar Therapeutics, a clinical-stage biopharmaceutical company, relies entirely on external funding for its research into rare diseases. This chart shows the market's overall debt load, allowing one to assess how the company's strategy for raising capital through debt or equity aligns with the standards of the risky biotech sector.
P/E of the company, segment and market as a whole
P/E - Larimar Therapeutics
Larimar Therapeutics is a biotech company developing drugs to treat rare protein deficiency diseases, such as Friedreich's ataxia. This chart shows the price-to-earnings ratio, which is currently irrelevant for the company. Investors' valuation is based on the potential of its lead drug and clinical trial data.
P/E of the market segment - Pharma neurology
Larimar Therapeutics is a clinical-stage biotech company. This chart shows the average valuation for the pharmaceutical sector. For Larimar, it serves as a contrast: while the industry is generally valued based on revenue, Larimar's valuation is entirely dependent on clinical trial expectations, not current financial performance.
P/E of the market as a whole
Larimar Therapeutics is a biopharmaceutical company focused on developing treatments for rare protein deficiencies, with a lead candidate for Friedreich's ataxia. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether LRMR's valuation is based on faith in its unique technology or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Larimar Therapeutics
Larimar Therapeutics is developing a therapy for rare diseases associated with a deficiency of the protein frataxin. The company's future profitability depends entirely on the success of its clinical programs. This graph reflects investor confidence that its scientific approach will lead to the development of an approved and marketable drug.
%20P%2FE%20Larimar%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Larimar-Therapeutics&v=1772611873955 "Chart of the company's future (projected) P/E Larimar Therapeutics")
Future (projected) P/E of the market segment - Pharma neurology
Larimar Therapeutics develops drugs to treat rare protein deficiency diseases, such as Friedreich's ataxia. The data here reflects analysts' collective bets on the success of its key development. It's a barometer of expectations for whether its CTI-1601 technology can become a breakthrough therapy and gain regulatory approval.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772611873972 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
Larimar Therapeutics is developing treatments for rare diseases associated with protein deficiencies. It's a high-risk biotech project. This graph of overall investor sentiment shows the market's risk appetite. Funding breakthrough, but not guaranteed, research requires significant optimism.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772611874008 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Larimar Therapeutics
Larimar Therapeutics develops therapies for rare protein deficiency diseases, such as Friedreich's ataxia. This chart reflects the financial costs of clinical trials. It shows the investment in research, with the ultimate goal being regulatory approval, which would completely transform the company's financial picture.
Profit of companies in the market segment - Pharma neurology
Larimar Therapeutics is a clinical-stage biopharmaceutical company developing therapies for rare diseases. Its financial history is one of investment in research. Future profitability depends entirely on the success of clinical trials and regulatory approval. This is a classic example of high-risk biotech, where one successful drug can change everything.
Overall market profit
Larimar Therapeutics is a clinical-stage biotech developing therapies for rare diseases. Its value is determined by scientific advances, not economic cycles. However, the overall economic situation, reflected in this chart, influences stock markets and investor risk appetite, which is critical for attracting funding for further research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Larimar Therapeutics
Larimar Therapeutics is a clinical-stage biotech developing therapies for rare diseases such as Friedreich's ataxia. This chart shows analysts' speculative expectations. Future revenue is entirely dependent on clinical trial results and regulatory approval, which is a key milestone for the company.
%20profit%20of%20the%20company%20Larimar%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Larimar-Therapeutics&v=1772611874212 "Graph of future (projected) profit of the company Larimar Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma neurology
Larimar Therapeutics develops drugs to treat rare diseases caused by a deficiency of the protein frataxin. The revenue forecasts for the pharmaceutical sector, shown in the graph, reflect overall trends. This chart provides investors with context for assessing the enormous potential of Larimar's lead candidate, which targets a disease with no approved treatments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772611874294 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
Larimar Therapeutics is a biotech company developing therapies for rare diseases such as Friedreich's ataxia. Its research funding depends on investor sentiment in the biotech sector. A positive economic outlook, illustrated by this chart, creates a more favorable environment for raising capital for risky projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772611874368 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Larimar Therapeutics
Larimar Therapeutics is developing treatments for rare diseases associated with a deficiency of the protein frataxin. While in the clinical stage, it may not generate revenue. This chart shows how the market evaluates its scientific platform and the potential of its lead drug candidate, betting on future success in treating Friedreich's ataxia.
P/S market segment - Pharma neurology
Larimar Therapeutics is a biopharmaceutical company developing treatments for rare diseases caused by protein deficiencies, with a focus on Friedreich's ataxia. This chart shows the average revenue estimate in the pharmaceutical industry. It helps understand the market premium for the potential of orphan disease drugs.
P/S of the market as a whole
Larimar Therapeutics develops treatments for rare protein deficiency diseases, such as Friedreich's ataxia. The company's potential depends on the success of its lead drug candidate. This chart shows the overall market revenue valuation landscape, providing a backdrop for analyzing biotech companies with future revenue potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Larimar Therapeutics
Larimar Therapeutics is a biotech company developing therapies for rare diseases such as Friedreich's ataxia. This chart reflects investor estimates of the potential future revenue of its lead drug candidate. This estimate is entirely dependent on clinical trial success and subsequent regulatory approval.
%20P%2FS%20Larimar%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Larimar-Therapeutics&v=1772611874436 "The graph of the company's future (projected) P/S Larimar Therapeutics")
Future (projected) P/S of the market segment - Pharma neurology
Larimar Therapeutics is a clinical-stage biotech developing treatments for rare diseases caused by protein deficiencies. This chart compares market expectations for its future revenue with those of other neuroscience pharma companies. The valuation reflects investor expectations for the successful development of its core technology and regulatory approval.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772611874441 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
Larimar Therapeutics is a clinical-stage biotech company developing therapies for rare diseases such as Friedreich's ataxia. Its value is almost entirely dependent on the success of clinical trials. This graph of overall market expectations for Larimar has no direct bearing on its potential, as its potential is determined by science, not economic cycles.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772611874464 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Larimar Therapeutics
This chart shows the revenue of Larimar Therapeutics, a clinical-stage biotech focused on treating rare diseases associated with protein deficiencies. The lack of consistent revenue on the chart is normal for such a company. Any revenue likely represents payments from partners or grants, not sales of a commercial product.
Sales of companies in the market segment - Pharma neurology
Larimar Therapeutics is a biopharmaceutical company developing therapies for rare protein deficiency diseases, such as Friedreich's ataxia. This chart shows revenue in the neuroscience pharmaceuticals sector. It reflects the enormous unmet need in orphan diseases, where innovative approaches like those developed by Larimar can transform patients' lives.
Overall market sales
Larimar Therapeutics is developing a therapy for rare diseases such as Friedreich's ataxia. Demand for its potential drug is determined solely by medical indications, not economic cycles. However, long-term economic growth, as reflected in this graph, ensures stable funding for healthcare systems, which will be required to cover the cost of treatment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Larimar Therapeutics
Larimar Therapeutics is a clinical-stage biotechnology company developing therapies for rare diseases, specifically Friedreich's ataxia. This revenue projection chart is based entirely on expectations. Its dynamics reflect analysts' confidence in the potential of its lead drug candidate and the likelihood of its successful advancement through clinical trials.
%20sales%20of%20the%20company%20Larimar%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Larimar-Therapeutics&v=1772611874496 "Schedule of future (projected) sales of the company Larimar Therapeutics")
Future (projected) sales of companies in the market segment - Pharma neurology
Larimar Therapeutics is a biopharmaceutical company developing treatments for rare diseases caused by protein deficiencies. Its lead candidate targets Friedreich's ataxia, a severe neurological disorder. This chart shows projected revenue for the neuroscience sector, reflecting the potential for drugs targeting rare (orphan) diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772611874505 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
Larimar Therapeutics develops drugs to treat rare diseases caused by protein deficiencies. Its success depends on scientific breakthroughs and clinical trial results. However, the overall economic stability reflected in its forecasts is important for attracting the long-term investment needed to bring such complex drugs to market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772611874509 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Larimar Therapeutics
Larimar Therapeutics develops therapies for rare neurological diseases. Currently in the clinical stage, the company is fully focused on science. This chart is a financial reflection of its R&D efforts. It shows the required investment and operating losses on the path to the potential development and commercialization of a life-saving drug.
Market segment marginality - Pharma neurology
Larimar Therapeutics is a biopharmaceutical company specializing in the development of treatments for rare diseases caused by frataxin deficiency, such as Friedreich's ataxia. This chart shows its financial performance. For a clinical-stage company, profitability reflects not sales but the efficiency of capital management and R&D expenditures compared to peers.
Market marginality as a whole
Larimar Therapeutics is a biotech company developing treatments for rare diseases caused by protein deficiencies. Its value and prospects are independent of the general economic cycles shown in this chart. The key factors are the success of clinical trials and regulatory approval of its drugs, which can create significant value for shareholders.
Employees in the company, segment and market as a whole
Number of employees in the company Larimar Therapeutics
Larimar Therapeutics is a clinical-stage biotech company developing therapeutics for rare diseases. This graph shows a small team of scientists. A small staff is typical for a company focused on R&D. Changes in headcount will signal key milestones in clinical trials.
Share of the company's employees Larimar Therapeutics within the market segment - Pharma neurology
Larimar Therapeutics is a clinical-stage biotech company developing therapies for rare diseases. Its team is a small, focused group of scientists. This graph illustrates the typical structure of such companies: the tiny staff emphasizes that its core value lies in intellectual property and scientific progress, not human resources.
Number of employees in the market segment - Pharma neurology
Larimar Therapeutics is a biotech company developing a treatment for the rare genetic disorder Friedreich's ataxia. This chart illustrates the focus and risks of a single product. The growth of the small research team is directly dependent on progress in clinical trials and regulatory decisions, which are key events for the company.
Number of employees in the market as a whole
Larimar Therapeutics is a biotech company developing therapies for rare diseases associated with protein deficiencies. Its staff consists of highly specialized scientists. The presented employment chart highlights that in the world of cutting-edge science, hiring is determined not by the state of the economy, but by research progress and the ability to attract funding for long development cycles.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Larimar Therapeutics (LRMR)
Larimar Therapeutics is developing a treatment for Friedreich's ataxia, a rare genetic disorder. It's a clinical-stage R&D company. This chart illustrates the enormous market value per scientist. It's a classic example of biotech, where capitalization is based on investors' hopes for clinical success and future market dominance.
%20of%20the%20company%20Larimar%20Therapeutics%20(LRMR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Larimar-Therapeutics-LRMR&v=1772611874783 "Chart of market capitalization per employee (in thousands of dollars) of the company Larimar Therapeutics (LRMR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
Larimar Therapeutics is a biotech company developing treatments for rare diseases. In this field, a company's value often depends on the success of a single key drug. This chart shows how highly the market values the potential of their lead development relative to the small team of scientists working on it, compared to other biotech companies.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772611874811 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
Larimar Therapeutics is a biopharmaceutical company developing therapies for rare diseases. This metric clearly illustrates the biotech model: market capitalization reflects not current revenue, but the potential value of a single drug in development. This allows a small research team to achieve a huge market valuation.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772611874815 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Larimar Therapeutics (LRMR)
Larimar Therapeutics is a clinical-stage biotech company developing treatments for rare diseases. They are not profitable. This chart shows their loss per employee. This is typical for an R&D company and reflects the cost of their scientific research. Investors use this metric to assess their capital burn rate.
%20Chart%20Larimar%20Therapeutics%20(LRMR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Larimar-Therapeutics-LRMR&v=1772611874849 "Company Profit Per Employee (in thousands of dollars) Chart Larimar Therapeutics (LRMR)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
Larimar Therapeutics is a clinical-stage biotech company working on treatments for rare diseases. It has no profit, only R&D expenses. This metric isn't a measure of profit, but rather a measure of capital efficiency: how much research they conduct for every dollar spent on salaries, compared to industry norms for R&D "burn."
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772611874859 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
Larimar Therapeutics is a clinical-stage biotech company specializing in rare neurological diseases. Like most R&D companies in this field, it has no commercial revenue. This chart shows the "investment burn rate" per employee—the amount the company spends on each scientist and administrator during drug development.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772611874888 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Larimar Therapeutics (LRMR)
Larimar Therapeutics is a clinical-stage biotech developing therapies for rare diseases. This chart shows the company in the research phase. No revenue per employee is normal, as all value is concentrated in the potential of their lead drug candidate.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Larimar-Therapeutics-LRMR&v=1772611874902 "Sales chart per company employee Larimar Therapeutics (LRMR)")
Sales per employee in the market segment - Pharma neurology
Larimar (LRMR) is a clinical-stage biotech developing treatments for rare protein deficiency diseases (e.g., Friedreich's ataxia). This chart shows the revenue (if any) generated by each employee (scientist). It reflects how productive the company's R&D platform is compared to other biotechs working on orphan diseases.
Sales per employee for the market as a whole
Larimar Therapeutics is a clinical-stage biopharmaceutical company developing therapies for rare diseases associated with protein deficiencies (such as Friedreich's ataxia). Their business is R&D, which does not yet reflect commercial effectiveness. Any revenue currently generated likely comes from affiliate fees, not sales.
Short shares by company, segment and market as a whole
Shares shorted by company Larimar Therapeutics (LRMR)
Larimar Therapeutics is a biotech company whose fate hinges on a single drug for the treatment of a rare disease (Friedreich's ataxia). This chart shows bearish bets. The bears are betting on the risks of clinical trials. The regulator has previously suspended the trials, and any further negative signal could send the stock plummeting.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Larimar-Therapeutics-LRMR&v=1772611874955 "Short Shares Chart for the Company Larimar Therapeutics (LRMR)")
Shares shorted by market segment - Pharma neurology
Larimar is a biotech company working on treatments for rare diseases, specifically Friedreich's ataxia. This chart shows bearish sentiment. "Shorts" here are a direct bet on failure. Investors are betting that their clinical trials will be halted by the FDA or will show no efficacy.
Shares shorted by the overall market
Larimar Therapeutics is a biotech company working on treatments for rare neurological diseases. Companies like this rely on the hope of successful clinical trials. This chart measures the overall market "fear." In moments of panic, investors often dump speculative biotechs, even if their science and research progress remain unchanged.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Larimar Therapeutics (LRMR)
Larimar Therapeutics is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Larimar-Therapeutics-LRMR&v=1772611874999 "RSI 14 indicator chart for the company's stock Larimar Therapeutics (LRMR)")
RSI 14 Market Segment - Pharma neurology
Larimar (LRMR) is a biotech company focused on *rare* neurological diseases (Friedreich's ataxia). The RSI_14_Seg for "Pharma neurology" (biotech) shows the overall sentiment. The chart helps us understand: is LRMR's volatility a reaction to its clinical trials, or is the entire biotech sector overheated?
RSI 14 for the overall market
Larimar (LRMR) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LRMR (Larimar Therapeutics)
Larimar (LRMR) is a biotech company developing therapies for rare diseases, specifically Friedreich's ataxia. This chart shows the average target price. It reflects analysts' speculative assessments of the likelihood of success in the company's clinical trials and regulatory resolution.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LRMR-Larimar-Therapeutics&v=1772611875021 "A chart showing analyst consensus forecasts for the expected stock price. LRMR (Larimar Therapeutics)")
The difference between the consensus estimate and the actual stock price LRMR (Larimar Therapeutics)
Larimar Therapeutics is a single-product biotech company. Their entire value is bet on the success of their lead candidate (CTI-1601) for the treatment of Friedreich's ataxia, a rare neurological disorder. This chart reflects analysts' speculative expectations regarding their clinical data and the binary (all-or-nothing) outcome of their R&D program.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LRMR-Larimar-Therapeutics&v=1772611875025 "A chart showing the difference between the consensus forecast and the actual stock price. LRMR (Larimar Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
Larimar Therapeutics is a biotech company developing a therapy for the rare disease Friedreich's ataxia. Its R&D has been suspended by the FDA. This chart shows analysts' overall expectations for the neuroscience sector, reflecting whether experts believe the company can overcome regulatory hurdles.
Analysts' consensus forecast for the overall market share price
Larimar Therapeutics (LRMR) is a clinical-stage biopharmaceutical company developing a drug to treat Friedreich's ataxia, a rare neurodegenerative disease. This chart shows the overall risk appetite in the market and serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Larimar Therapeutics
Larimar is a one-stop-shop biotech. Their value is almost entirely dependent on a single drug candidate (CTI-1601) for the treatment of a rare neurological disorder (Friedreich's ataxia). This chart is a summary indicator of their progress. It likely reflects the market's confidence in their clinical data and their difficult journey with the FDA (which previously suspended their trials).
AKIMA Market Segment Index - Pharma neurology
Larimar (LRMR) is a clinical-stage biotech focused on rare neurological diseases; the company is developing a novel drug (CTI-1601) for the treatment of Friedreich's ataxia. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this ultra-niche (R&D) rate (LRMR) differentiate it from the average pharma company?
The AKIM Index for the overall market
Larimar is a clinical-stage biotech company developing treatments for rare mitochondrial diseases (Friedreich's ataxia). This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this innovative orphan disease company.
